Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT102-A in Children With Phenylketonuria
NCT05948020Phase 1Completed
- Sponsor
- Children's Hospital of Fudan University
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Microbiome Therapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in phenylketonuria (PKU) comparing CBT102-A group with Placebo group (2 arms). Primary endpoint: Changes from Baseline in Blood Phenylalanine Concentration at Day 51. Started Sep 2023; status: completed.
02
Drugs
CBT-102
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05948020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948020.